Is MOLN's EPS growth sustainable long-term?

**MOLN's EPS growth is not currently sustainable long-term.** Here's why:

1. **Recent Performance**: Molecular Partners AG (MOLN) has reported a negative diluted EPS of $-12.39 million for the latest report period ending on December 31, 2024. This negative EPS indicates that the company has been unprofitable in the recent past.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|MOLN|MOLN.O|Molecular Partners|2024 Q1|23.488999773577472|-0.3771491956|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q2|6.592254562515889|-0.5115658344|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q3|-51.556135415907875|-0.5802937014|185|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|MOLN|MOLN.O|Molecular Partners|2024 Q1|-9.094307252675799|3037160.28692|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q2|271.8646016502543|1724866.54164|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q3|-70.98731426934468|806489.81766|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|MOLN|MOLN.O|Molecular Partners|2024 Q1|22.39672945795702|-1.25623960005E7|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q2|6.132965075266837|-1.677268677048E7|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q3|-55.24127017612381|-1.942681199544E7|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q4|47.367135001310025|-1.2386413728E7|185|

|code|Ticker|Name|Date|Operating Income YoY|Operating Income|market_code|
|---|---|---|---|---|---|---|
|MOLN|MOLN.O|Molecular Partners|2024 Q1|22.39672945795702|-1.25623960005E7|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q2|6.132965075266837|-1.677268677048E7|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q3|-55.24127017612381|-1.942681199544E7|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q4|47.3765069502058|-1.238420817E7|185|

2. **Growth Rate**: The company's diluted EPS has experienced a year-over-year decrease of 4.05%. This decline suggests that the company's earnings per share are trending downwards, which is not a sign of sustainability.

|code|Ticker|Name|Date|Net Income YoY|Operating Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|---|
|MOLN|MOLN.O|Molecular Partners|2024 Q1|22.39672945795702|22.39672945795702|-9.094307252675799|23.488999773577472|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q2|6.132965075266837|6.132965075266837|271.8646016502543|6.592254562515889|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q3|-55.24127017612381|-55.24127017612381|-70.98731426934468|-51.556135415907875|185|
|MOLN|MOLN.O|Molecular Partners|2024 Q4|47.367135001310025|47.3765069502058|||185|

3. **Analyst Views**: Despite the negative financials, TD Cowen has maintained a Buy rating on MOLN with a price target of CHF15. Analysts seem optimistic about the company's potential, particularly due to its innovative platforms and upcoming developments.
4. **Strategic Position**: Molecular Partners is known for its innovative radioligand therapy and immune-oncology platforms, which are advancing rapidly. These advancements could potentially lead to future growth and profitability.
5. **Financial Health**: The company's financial health, with more cash than debt and a strong current ratio, indicates a solid foundation to support future growth initiatives.

In conclusion, while MOLN's strategic position and potential for growth are positive signs, the current negative EPS and declining growth rate make it challenging to argue that the company's EPS growth is sustainable in the long term. However, the company's innovative platforms and analyst confidence suggest that there may be a path to profitability in the future.